Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Business Wire July 13, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at European Society for Medical Oncology 2016 Congress

Business Wire July 12, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online

Business Wire June 9, 2016

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology

Business Wire June 7, 2016

Provectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA

Business Wire June 7, 2016

Provectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page

Business Wire June 1, 2016

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 Plus Radiotherapy in Melanoma

Business Wire May 19, 2016

Provectus Biopharmaceuticals Announces Abstract Available Online of Trials in Progress; Abstract for Poster Presentation at ASCO Annual Meeting

Business Wire May 19, 2016

StockNewsNow.com Publishes May 2016 Update SNNLive Video Interview with Provectus Biopharmaceuticals, Inc.

PR Newswire May 17, 2016

Provectus Biopharmaceuticals Announces Publication of Article in Oncotarget Detailing PV-10’s Immuno-Ablative Mechanism of Action

Business Wire May 13, 2016

Provectus Biopharmaceuticals, Inc. Reports First Quarter 2016 Financial Results

Business Wire May 10, 2016

Investor Calendar Invites You to the Provectus Biopharmaceuticals First Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday May 10, 2016

Accesswire May 9, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on Tuesday, May 10, 2016, at 4 pm Eastern Daylight Time

Business Wire May 4, 2016

Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery

Business Wire April 28, 2016

Provectus Biopharmaceuticals to Participate in Panel at Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact

Business Wire April 27, 2016

Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016

Business Wire April 22, 2016

Provectus Biopharmaceuticals Reports Trials in Progress Abstract Accepted for Poster Presentation at ASCO Annual Meeting

Business Wire April 20, 2016

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter and Year End 2015 Financial Results

Business Wire March 30, 2016

Provectus Biopharmaceuticals to Host Its Quarterly Year-End 2015 Financial Business Update Conference Call Wednesday, March 30, 2016 at 4 pm (EDT)

Business Wire March 24, 2016

Provectus Biopharmaceuticals Announces Abstract Publicly Available for Poster Presentation on PV-10 in Combination Therapy and T Cell Mediated Immunity

Business Wire March 18, 2016